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Abstract 
Drug induced liver injury is an important clinical entity. It can be grouped into cholestatic 
liver injury, hepatocellular liver injury and mixed liver injury. Cholestatic liver injury is 
characterized by a reduction in bile flow and retention within hepatocytes of cholephilic 
compounds such as e.g. bile salts that cause hepatotoxicity. 
Bile salts are largely taken up in a sodium-dependent manner and to a minor part in a sodium-
independent manner (into) by hepatocytes. The former process is mediated by the sodium-
(dependent) taurocholate cotransporting polypeptide (NTCP) and the latter by the organic 
anion transporting polypeptides (OATPs). OATPs have a broad substrate specificity and 
mediate uptake of a many drugs into hepatocytes. Bile salts are exported from hepatocytes 
into the biliary tree by the bile salt export pump (BSEP). Inhibition of BSEP by drugs or drug 
metabolites leads to drug-inuduced cholestasis. BSEP can be inhibited directly from within 
the hepatocyte, or indirectly by a mechanism that first requires canalicular secretion of the 
perpetrator. In cholestatic liver disease, expression of hepatocellular uptake transporters is 
generally reduced, while the expression of the canalicular export systems tends to be 
preserved. This adapatation is controlled by nuclear receptors and transcription factors. 
Genetic variants of BSEP may be a risk factor for drug-induced cholestasis. So far, studies 
have associated the c.1331T variant of the ABCB11 gene coding for a V444A substitution in 
BSEP as a potential risk factor. Additional risk factors may be genetic variants of uptake 
transporters or other export transporters for drugs or their metabolites. 
 
Introduction 
The liver is a key organ in protecting the body from potentially harmful xenobiotics and is 
central in the metabolism and elimination of xenobiotics. As such, it is constantly challenged 
by toxic substances and metabolites and it is not surprising that the liver is a major target for 
adverse drug reactions, which lead to drug induced liver injury (DILI). DILI is a very 
important clinical entity. The incidence of serious adverse drug reactions in hospitalized 
patients may be up to 6 % and may be contribute up to 0.3 % of all deaths of inpatients (1). 
Adverse drug reactions account for over 50 % of cases presenting with acute liver failure (2). 
A recent US study highlighted that in severe cases, transplant-free survival is poor (27 %) and 
that the overall survival with transplanted patients included is 66 % (3). DILI is categorized 
into drug-induced cholestasis, drug induced hepatitis or mixed liver injury (4). In medical 
inpatients, cholestatic and mixed liver injury may account for up to 30 % of cases with DILI 
(5). DILI is also a major issue in drug development, where it often leads to attrition of drugs 
during development or later to removal of drugs from the market (6,7). 
 
Bile formation 
Bile formation is a key function of the liver. Disturbances in bile formation lead to a reduction 
of bile flow, a pathophysiologic process which is called cholestasis. Bile salts are synthesized 
from cholesterol in a complex series of highly orchestrated biosynthetic steps involving 
among others peroxisomes in hepatocytes (8). In hepatocytes, new synthesized bile salts are 
mixed with bile salts entering from the portal blood and secreted via the canalicular 
membrane into the canaliculi, which are the functional starting point of the biliary tree. The 
biliary tree ultimately drains into the duodenum. In the small intestine, bile salts are essential 
for lipid digestion and the absorption of fat and fat soluble vitamins (9,10). Bile salts are 
absorbed to more than 90 % along the small intestine and transported back by the portal blood 
to the liver (11), where they are taken up into hepatocytes and again secreted into the 
canaliculi. This roundtrip of bile salts between the intestine and the liver is termed 
enterohepatic circulation. 
 
Uptake of bile salts from sinusoidal blood into hepatocytes is predominantly sodium-
dependent and to a minor part sodium-independent. The sodium-dependent uptake of bile 
salts is mediated by the sodium taurocholate cotransporting polypeptide (NTCP, SLC10A1), 
which is expressed in a polar manner at the basolateral plasma membrane of hepatocytes 
(11,12). NTCP has a preference for conjugated bile salts over unconjugated bile acids. The 
sodium-independent portion of the bile salt uptake is mediated by organic anion transporting 
polypeptides (OATPs). OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3) and OATP2B1 
(SLCO2B1) are expressed at the basolateral plasma membrane of hepatocytes, although 
OATP2B1 appears not to be a bile salt transporter (13-15). OATPs have a preference for 
unconjugated bile acids over conjugated bile salts (16), which was recently confirmed in 
genetically modified mice (17,18). Importantly, OATPs mediate uptake of the metabolic 
endproduct bilirubin (19-21) and of numerous xenobiotics including many widely prescribed 
drugs (22,23). In contrast, the role of NTCP in the hepatocellular uptake of drugs seems to be 
minor (12). 
 
After their uptake into hepatocytes, bile salts reach the canalicular plasma membrane by a 
mechanism that has not yet been characterized in detail, but probably bound to cytoplasmic 
proteins (12). The free intracellular bile salt concentration in hepatocytes is probably less than 
1 µM in rats (24) and may be comparably low in human hepatocytes (25). Export into the 
canaliculus is mediated by the bile salt export pump BSEP against a large concentration 
gradient. BSEP (ABCB11) is a member of the ATP-binding cassette (ABC) transporter super 
family (12,26,27). The canalicular secretion of bile salts represents the rate limiting step of 
bile salt transport across hepatocytes (13,28). Due to its strategic position in hepatic bile salt 
secretion, the proper functioning and regulation of this transporter is essential for hepatocyte 
viability since bile salts have detergent properties and easily become cytotoxic (29). 
 
In addition to bile salts, bile is rich in phospholipids and organic anions such as bilirubin 
conjugates. Phospholipids are the main component of biliary lipids and need multidrug 
resistance protein 3 (ABCB4) for entering the canalicular bile (30). This ABC transporter 
translocates the main biliary lipid phosphatidylcholine from the inner to the outer leaflet of 
the canalicular membrane. Bile salts, by acting as detergents, release phosphatidylcholine 
from the outer canalicular leaflet into the canaliculus, where the two constituents form mixed 
micelles (31). These mixed micelles act as acceptors for poorly water soluble substances, a 
prototypic example being cholesterol. Cholesterol release from the canalicular membrane is in 
part mediated by the heterodimeric ABC transporter ABCG5/ABCG8 (ABCG5/ABCG8) (32). 
In addition to acting as carriers for poorly water soluble substances, mixed micelles are 
needed to lower the toxic action of biliary bile salts against cholangiocytes to prevent bile salt 
induced injury of the bile ducts (33,34). Biliary organic anions other than bile salts are mainly 
conjugates of bilibubin and glutathione. Often, drug metabolites excreted into bile are also 
organic anions. These compounds are transported by the two ABC transporters multidrug 
resistance-associated protein 2 (MRP2, ABCC2) and ABCG2 (ABCG2). 
 
In summary, bile formation is one of the key functions of the liver and requires an intricate 
interplay of transport systems expressed at the basolateral and canalicular membrane of 
hepatocytes. The ABC transporters expressed in the canalicular membrane are able to work 
against steep concentration gradients and thereby keep the concentration of their respective 
substrates low within hepatocytes. An interference with these transporters, either by inherited 
or acquired disturbance of their function can potentially lead to an accumulation of toxic 
substances in hepatocytes and in turn to liver disease. 
 
Clinical Features of Drug Induced Cholestasis 
Diagnosis of DILI and DIC depends on a detailed clinical assessment of the patient and 
individual drugs, which can lead to a specific clinical phenotype (35-37). Diagnosis of DILI 
includes chronological criteria, exclusion of other causes and positive clinical criteria (1,35-
40). A classification system such as e.g. established by the Council for International 
Organization of Medical Sciences is certainly helpful for identifying patients with drug-
induced cholestasis among the many other forms of DILI (4). Bland cholestasis is associated 
with elevated alkaline phosphatase and elevated bile salts in plasma and usually rapidly 
reverts upon discontinuation of the culprit drug. Mild forms of DILI may be asymptomatic 
and vanish as a consequence of adaptation (41). 
 
Hepatocellular Drug Uptake and Intracellular Drug Concentrations 
NTCP is a secondary active transporter and can mediate uptake of its substrates against a 
concentration gradient, leading to a potentially higher intracellular concentration than in the 
sinusoidal blood plasma. The driving force of OATPs is so far not fully understood and 
remains controversial (15,36). OATPs are most likely bidirectional transporters that exchange 
anions against each other. Evidence that intracellular anions are effluxed upon OATP-
mediated substrate uptake has so far been presented for glutathione (42), glutathione-
conjugates (43) and bicarbonate (44,45). In addition, transport activity of almost all OATPs 
tested so far is activated by a low extracellular pH (45). As there is an in to out gradient of 
glutathione over the hepatocellular plasma membrane, uptake in exchange for glutathione 
could potentially work against a concentration gradient leading to an intracellular 
accumulation of OATP substrates, e.g. drugs. For example, in rats glibenclamide was 
observed to be fifty times higher in the liver compared to serum indicating a concentrative 
uptake mechanism (46). As coadministration of the OATP-inhibitor rifampicin with 
glibenclamide leads to an increase of glibenclamide exposure in humans (47), glibenclamide 
is a potential substrate for OATPs. Higher hepatocellular concentration of glibenclamide 
compared to plasma is in line with the observation that indocyanine green, which is 
transported into hepatocytes by OATP1B3 and also by NTCP (48) shows ten-fold higher 
concentrations in hepatocytes than in the plasma of rats (49). Furthermore, the transport 
activity of OATPs may be modulated by endo- and xenobiotics, such as prostaglandins (50), 
estrone-3-sulfate (51), estradiol-17β-glucuronide (52), clotrimazole (53) or herbal extracts 
(54,55). This modulation can, at least in part, be due to different substrate binding sites of 
different OATPs (54). All these different transport mechanisms may individually play a role 
in OATP-mediated drug uptake into hepatocytes and preclude a prediction of the intracellular 
drug concentration from serum values. It is however clear that DILI injury including drug-
induced cholestasis correlates with the dose of the drug, which in turn impacts intracellular 
drug concentrations (56). 
 
In addition to uptake, metabolism and efflux of drugs from hepatocytes are also important 
steps in overall drug disposition that affect intracellular drug concentrations. In the canalicular 
membrane, multidrug resistance protein 1 (MDR1, ABCB1) is a major contributor to 
hepatocellular export of drugs into the canaliculus. The substrate specificity of MDR1 is very 
broad and includes numerous drugs (57,58). The substrates of MDR1 are electrically neutral 
or positively charged organic molecules and include anticancer drugs, immunosuppressants, 
antifungals, CNS drugs, antihistamines, antihypertensives, protease inhibitors and 
xenobiotics. Since MDR1 is expressed at many organ boundaries, it is a key determinant in 
drug and xenobiotic disposition and in the toxicity of such compounds (59). MRP2 exports 
drugs, xenobiotics and numerous phase II metabolites (58,60,61) and ABCG2 transports a 
long list of drugs and also toxins (62-64). In hepatocytes, drug and drug metabolite excretion 
also occurs back into the portal plasma. This step is mediated by MRP3 and MRP4, which 
mediate export of drugs including some antimetabolites and drug metabolites across the 
basolateral plasma membrane of hepatocytes (65). 
 
In summary, the hepatocyte is equipped with an intricate network of uptake and efflux 
transporters for drugs and their metabolites. Drug metabolism both biotransforms and 
generates substrates of these transporters. Consequently, transport and metabolism are linked 
in a complex network via substrate levels and processes that regulate gene expression (66). 
 
Mechanisms of BSEP Inhibition 
Inhibition of BSEP leads to a reduction of biliary bile salt secretion and bile flow as well as to 
accumulation of bile salts within hepatocytes. If the inhibition persists, BSEP inhibition leads 
to acquired clinical cholestasis, often of the bland type. Drug examples originally shown to 
inhibit human and rat BSEP/Bsep are cyclosporine, rifampicin, rifamycin, glibenclamide or 
bosentan (67-71). All these drugs have been shown to lead to acquired cholestasis in 
susceptible patients. The cholestatic mechanism of the dual endothelin receptor antagonist 
bosentan has been worked out in considerable detail. Bosentan and its main metabolite enter 
hepatocytes via uptake through OATP1B1 and OATP1B3 and bosentan is eliminated by 
biliary excretion (72). During clinical trials, bosentan was found to cause reversible, 
asymptomatic transaminase elevations in some patients (73). In the same patients, plasma bile 
salt levels increased in proportion to the dose of bosentan. In rats, bosentan treatment also 
leads to an elevation of plasma bile salt levels, which is more pronounced after 
coadministation of glibenclamide (73). Both, rat and human Bsep/BSEP are competitively 
inhibited by bosentan, which strongly suggests that in vivo - in patients with elevated bile 
salts - bosentan has the same principle of action. In these patients, no elevation of bilirubin 
was observed (73), which supports the concept of a specific bosentan - BSEP interaction. 
Further investigation of bosentan-induced cholestasis in rats revealed a more complex 
mechanism of bosentan-induced cholestasis. In rats, administration of bosentan leads to a 
stimulation of bile flow (74) This is not in line with the basic concept of cholestasis, which is 
defined by a reduction of bile flow. In this animal study, no impact of bosentan on bile salt 
output was observed, but a reduction in biliary phospholipid secretion (74). Increased 
canalicular bile flow with constant bile salt output leads to a lower intracanalicular bile salt 
concentration. As biliary phospholipid secretion is critically dependent on canalicular bile salt 
concentrations (31), a reduction in biliary lipid secretion might adversely alter the lipid 
asymmetry of the canalicular membrane, which in turn could lead to an intracellular 
accumulation of bile salts (75). This choleretic effect of bosentan in rats is dependent on the 
presence of functional Mrp2 in the canalicular membrane (74). Indeed, while the transport 
activity of rat and human BSEP is inhibited in Sf9 cell vesicles by bosentan, this drug 
stimulates the transport activity of rat and human MRP2 (76). The list of drugs that have until 
now been demonstrated to inhibit BSEP is long (77,78). Morgan and coworkers demonstrated 
that drugs with IC50 values in the low µM range towards BSEP are known to have clinical 
liabilities (77). Dawson and coworkers found no clear distinction between unbound plasma 
Cmax values, IC50 values and DILI in man (78), supporting the concept that other factors such 
as for example drug uptake into hepatocytes contribute to the development of acquired 
cholestasis. 
 
Troglitazone is a drug, which was withdrawn from the market as a consequence of severe 
hepatotoxicity. The detailed mechanism of troglitazone toxicity remains somewhat elusive, 
but involvement of mitochondrial toxicity has emerged as an agreed concept (79,80). In rats, 
the main metabolite of troglitazone is troglitazone sulphate, which is eliminated into bile (81). 
Administration of troglitazone to rats leads to a reduction of bile flow, i.e. cholestasis (82). 
Troglitazone and its sulphated metabolite are potent inhibitors of rat Bsep (83). Consequently, 
troglitazone, which is also an inhibitor of dog and human Bsep/BSEP (84), can lead to an 
accumulation of bile salts in hepatocytes, which in turn are toxic to mitochondria (29). This 
process aggravates the negative impact of troglitazone to mitchondria and leads to mixed 
(hepatocellular and cholestatic) liver injury. The thiazolidinediones, rosiglitazone and and 
ciglitazone, inhibit bile salt transport into rat canalicular plasma membrane vesicles, 
suggesting a class effect on Bsep inhibition (85). Indeed, rosiglitazone is also associated with 
liver injury (86). 
 
Oral contraceptives may lead to acquired cholestasis (87,88) and steroid metabolites are 
associated with the onset of intrahepatic cholestasis of pregnancy (87,89-92). Application of 
estradiol-17β-glucuronide and progesterone sulfate leads to acute cholestasis in rats (93,94). 
Both steroid metabolites do not inhibit Bsep expressed in Sf9 cells, but require the 
coexpression of Mrp2 (67,94,95), indicating transinhibition of Bsep. An alternative 
explanation for this finding is an interaction of Mrp2 with Bsep in the canalicular membrane 
that is fostered by estradiol-17β-glucuronide and leads to Bsep inhibition (96). The epidermal 
growth-factor receptor (HER1/HER2) inhibitor PKI166 has been reported to exhibit a similar 
pattern of inhibition (97). 
 
Impact of Elevated Intracellular Bile Salt Levels on Transporter Expression 
Inhibition of BSEP by drugs in susceptible patients may lead to bland cholestasis or may 
aggravate cholestasis with subsequent mixed liver injury. The mechanism of BSEP inhibition 
can either be competitive - i.e. direct - or may require the action of an additional transporter, 
such as Mrp2 and may consequently be indirect. Any impairment of BSEP will lead to an 
intracellular accumulation of bile salts. Within hepatocytes, bile salts activate a bile salt 
sensor, the nuclear transcription factor farnesoid-X-receptor (FXR, NR1H4) (98,99). FXR acts 
as a key regulator of metabolic processes (100). Generally, activation of FXR by increased 
bile salt concentrations in hepatocytes down-regulates the uptake systems for bile salts and 
maintains or upregulates bile salt efflux systems. (101). FXR upregulates the expression of 
small heterodimer partner (SHP), which in turn directly represses the expression of rat Ntcp 
(102) and down-regulates the expression of human NCTP indirectly via the glucocorticoid 
receptor (103). The impact of FXR on the expression of SLCO1B1 has been reported with 
conflicting results. While an earlier publication reported HNF1-mediated down-regulation of 
OATP1B1 expression after activation of FXR (104,105), thereby explaining the decrease in 
OATP1B1 mRNA expression  that was found in liver tissue from patients with cholestatic 
liver disease (106), another group reported a direct activation of the expression of OATP1B1 
after pharmacologic activation of FXR (107). To our knowledge, FXR dependent regulation 
of the expression of OATP2B1 has not yet been reported and unpublished data from our 
group showed a complex response element within the 5' flanking region of the human 
SLCO2B1 gene that appear to be repressed by monomeric FXR (Eloranta and Kullak-Ublick, 
unpublished) (108). The promoter of SLCO1B3 coding for the third hepatocellular OATP is 
directly transactivated by FXR (109). The ABCB11 gene is also subject to direct 
transactivation by FXR (110) and ABCC2 transcription also appears to be responsive to FXR 
activation (111). The ligand binding to FXR is rather specific and to date, only a limited 
number of synthetic agonists exist (112,113). Bile salts are derived from cholesterol, which in 
turn may also be metabolically converted to oxysterols. (114). Oxysterols activate the liver X 
receptors (LXR,) LXRα (NR1H3) and LXRβ (NR1H2) (112). The promoter of SLCO1B1 has 
been shown to contain a LXRα response element (107). Expression of BSEP is also 
upregulated by oxysterols, but this regulation involves FXR rather than LXR (115). Drugs and 
xenobiotics are ligands of the pregnane X receptor (PXR, NR1I3) and/or of the constitutive 
androstane receptor (CAR, NR1I2) (112,113,116). Next to activation of phase I and phase II 
detoxification processes, these nuclear receptors also regulate transporter expression. So far, 
direct activation by PXR could only be shown for the rat Slco1a4 gene (117). However, 
OATPs mediate uptake of a considerable number of PXR or CAR ligands and as such are 
indirectly involved in the regulation of drug and xenobiotic metabolism in hepatocytes (118). 
At the transcriptional level, the expression of MRP2is positively regulated by both PXR and 
CAR (111,119). This may help to protect hepatocytes from potentially toxic metabolites of 
drugs and xenobiotics. 
 
Data on alterations of transporter expression levels in human liver tissue from patients with 
drug-induced cholestasis have not been published. However, information on transporter 
expression in other forms of liver disease, including cholestatic liver disease has been 
investigated. Patients suffering from progressive familial intrahepatic cholestasis, a severe 
cholestatic liver disease, show unchanged NTCP expression at the mRNA level but reduced 
protein levels (120).In patients with biliary atresia, a form of obstructive cholestasis, NTCP 
mRNA is decreased, but increases after restoration of bile flow (106,121,122). In primary 
biliary cirrhosis (PBC), NTCP expression is not affected in early stages, but is decreased in 
late stages (106,123,124). Wherease patients with chronic hepatitis C do not display altered 
NTCP expression, cholestatic hepatitis leads to reduced NTCP expression (106). After liver 
transplantation, both the expression of NTCP mRNA as well as hepatic bile salt output are 
increased (125). In patients with advanced PBC or icteric cholestasis OATP1B1 shows lower 
expression than in controls (106,124). OATP1B1 and OATP1B3 are also decreased in late 
stages of PBC (123) and OATP1B1 was found to be reduced in primary sclerosing cholangitis 
(PSC)(126). In patients suffering from obstructive cholestasis predominantly as a 
consequence of cancer of the biliary tract or of the pancreas, successful percutaneous drainage 
leads to a mildlyfuzzy canalicular staining, while poorly drained patients show reduced and 
fuzzy canalicular BSEP staining and a slight decrease of BSEP mRNA (127). Pediatric 
patients with biliary atresia have no change of BSEP protein, but BSEP mRNA is decreased 
to an extent that depends on the stage of the disease (128). BSEP is down-regulated in patients 
with inflammatory cholestatic liver disease (106), but appears to be preserved in PBC 
(123,124). In fact, induction of BSEP has even been reported in PBC (129). The organic anion 
and drug-metabolite efflux pump MRP2 is down-regulated in primary sclerosing cholangitis 
primary sclerosing cholangitis (126) and is decreased in late stages of PBC (123,130) but was 
found to be preserved in other studies (124). Icteric cholestasis lowers expression of MRP2, 
while its mRNA was found to be unchanged (106), a finding that could not be confirmed in a 
different study (129) and was found to be variable in a third study (131).  
 
Taken together, uptake systems in hepatocytes tend to be down-regulated in human 
hepatocytes under various forms of liver disease, while canalicular export pumps usually are 
preserved in such conditions. These findings in humans are mirrored in many animal studies 
with models for liver disease and have been summarized elsewhere (132). 
 
Susceptibility Factors for Drug Induced Cholestasis 
While drug induced cholestasis (DIC) is a relevant clinical entity, the risk for incurring (DIC) 
is very low (133). However, identification of risk factors that render patients susceptible to 
DIC bears the potential to further reduce the incidence of DIC, which in turn will improve the 
outcome and the quality of life of patients and lower the financial burden to the health care 
systems. Our understanding of the mechanisms of DIC in humans has advanced considerably 
in recent years. For ethical reasons, any hypothesis developed can only be tested in animals, 
which may or may not apply to the human situation. This is exemplified by progressive 
familial intrahepatic cholestasis type 2 (PFIC2). These patients have mutations in the ABCB11 
gene coding for BSEP (134) and develop severe liver disease. In contrast, mice with a 
disrupted Abcb11 gene have only a mildly impaired liver function (135). 
 
BSEP is a likely susceptibility factor for DIC, as impaired BSEP function is an underlying 
molecular mechanism of hepatotoxic adverse drug events. Analysis of the protein expression 
of several canalicular ABC transporters revealed a considerable interindividual variability of 
the expression of BSEP in healthy human liver tissue (136). Individuals with lower protein 
levels of BSEP could be at risk for developing DIC (27). The hypothesis behind this concept 
is supported by a patient with benign recurrent BSEP deficiency syndrome. This patient is a 
compound heterozygote for two mutations in the ABCB11 gene, E297G and R432T (137). In 
Sf9 cells, both mutations show only residual transport activity. Thus, although functional 
BSEP capacity may have sufficed to uphold bile salt excretion under normal physiologic 
situations, the threshold for inhibition of BSEP activity and bile salt export from hepatocytes 
was lower. One of the cholestatic episodes of this patient was putatively linked to nonsteroidal 
anti-inflammatory drugs, which are known to be a challenge for hepatocytes. While multiple 
studies on ABCB11 gene polymorphisms and variants have been published, the 
nonsynonomous c.1331T>C and c.2029A>G polymorphisms in exons 13 and 17, respectively 
are consistently reported with frequencies greater than 0.5 % in independent cohorts (138-
142). Genotyping of the individuals contributing to the cohort of liver samples used for 
expression analysis revealed that individuals carrying at least one c.1331C allele tended to 
have lower BSEP expression levels (136). As individuals homozygous for the c.1331C allele 
were all found in the low range of BSEP expression, this allele could potentially be a 
susceptibility factor for DIC and acquired cholestasis. Kinetic characterization of the two 
BSEP variants in the Sf9 cell expression system revealed no difference (140). An association 
of the c.1331C allele with acquired cholestasis was confirmed in patient cohorts with DIC 
(140) and cholestasis of pregnancy (143,144). Interestingly, the same polymorphism 
correlates with progression to cirrhosis in hepatitis C genotype 2 and 3 patients (145) and 
shows an association with a lower sustained viral response for hepatitis C genotype 2 and 3 
(146). The underlying mechanism could be a positive correlation between intracellular bile 
salt levels and hepatitis virus C replication (101). An association of the c.1331C allele with 
acquired forms of cholestasis has also been found in several case reports (12,70). However, a 
study on a Swedish cohort of women presenting with cholestasis of pregnancy found no 
association with common ABCB11 haplotypes (147). Methodologically, this study analyzed 
haplotype distribution, while all the previous studies investigated single nucleotide 
polymorphisms. 
 
To our knowledge, up to now no studies analyzing specifically the role of MRP2 variants in 
the susceptibility to DIC have been reported. However, ABCC2 haplotypes have been 
associated with liver injury induced by drugs or herbal remedies (148) and with diclofenac 
induced hepatotoxicity (149). These findings make it likely that an association of MRP2 
variants with susceptibility to DIC is possible. MRP2 variants have also been associated with 
altered drug disposition (150). With respect to ABCG2, MRP3 and MRP4, pharmacogenetic 
studies on the role of ABCG2, ABCC3 and ABCC4 in drug disposition or efficacy showed 
conflicting results (150). Hence, a potential role of ABCG2, MRP3 and MRP4 variants in 
DIC remains to be investigated. Its capacity to transport a wide variety of drugs and its impact 
on the disposition of its substrates has led to many studies that have investigated the 
pharmacogenetics of MDR1 in relation to drug disposition (150). The results of these studies 
have been highly inconsistent, in some cases contradictory. A majority of recent meta-
analyses found no impact of the synonymous c.3435C>T polymorphism of ABCB1 on 
pharmacokinetics and pharmacodynamics as well as susceptibility to diseases (150). 
Consequently, it seems fair to assume that MDR1 is not an important susceptibility factor for 
DIC. Additional genetic risk factors for DIC are genes coding for phase I and phase II 
enzymes of drug metabolism (2,37,151). 
 
Even the strongest known associations between genotype and the phenotype of DILI (e.g. the 
HLA-B*5701 genotype in flucloxacillin-induced liver injury (152) ultimately account for 
only a small fraction of the overall risk for the phenotype in question to occur. Additional 
factors such as drug doses, preexisting liver disease, sex, age and lifestyle constitute 
additional susceptibility factors for DIC (2,56,153,154). The low overall incidence of this 
adverse drug reaction makes the assessment of the relative importance of each individual risk 
factor difficult. This is where systematic pharmacoepidemiological studies will be of value, 
since they combine an extensive survey of patient risk constellations with the clinical 
appraisal of individual cases, in tribute to the observation that no two cases of DILI or DIC 
are ever the same. 
 
Outlook 
The impairment of membrane transport is now recognized as an important mechanism in the 
pathogenesis of DILI, notably drug-induced cholestasis. Several hepatotoxic drugs have been 
shown to inhibit BSEP, although additional mechanisms such as mitochondrial toxicity and 
immune-mediated liver damage are usually required for clinically severe liver injury to occur. 
Of all the transporters characterized to date, BSEP is the best characterized in connection with 
a cholestatic pattern of injury. The V444A genetic variant, which is common in the 
population, appears to confer a risk for drug-induced and other forms of acquired cholestasis, 
although other BSEP variants have also been identified. The role of the phospholipid 
translocator MDR3 in drug-induced cholestasis is still unclear. A functional in vitro assay for 
MDR3 transport activity is not available to date, making inhibition studies difficult. It seems 
likely that bile duct injury inflicted by drugs may in some cases be caused by inhibition of 
MDR3 mediated phospholipid excretion into the bile ducts, but this area of research remains a 
challenge for the future. In addition to the expression and genotype of transporters 
themselves, the intricate network of transcriptional and epigenetic regulatory mechanisms that 
affect transporter activity are under intense investigation and new mechanisms by which 
drugs can adversely affect membrane transport are likely to emerge from this line of study. To 
date, functional testing of BSEP and MRP2 inhibition by drugs is commonly required by the 
FDA in the context of liver signals during drug development, but interpretation of the results 
still requires an exact analysis of the individual clinical presentation in connection with the in 
vitro findings. 
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